Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) to merge with RDD Pharma creating new gastroenterology company focused on specialty, rare and orphan diseases.

Intuitive Venture PartnersOctober 7, 2019innovate biopharmaceuticals, 2019

Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts Focusing on the Molecular Biology and Pharmacology of Larazotide for the 2019 Digestive Disease Week Conference

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced that three abstracts were accepted for presentations during the 2019 Digestive Disease Week (DDW) conference.

Intuitive Venture PartnersFebruary 25, 2019innovate biopharmaceuticals, 2019

Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced today that Patrick H. Griffin, M.D., F.A.C.P. has joined as the acting head of clinical development.

Intuitive Venture PartnersNovember 26, 2018innovate biopharmaceuticals, 2018

Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) announces it intends to present at the Jefferies 2018 London Healthcare Conference. The conference is being held on November 14-15, 2018.

Intuitive Venture PartnersOctober 31, 2018innovate biopharmaceuticals, 2018

Innovate Biopharmaceuticals Announces Participation at the Ladenburg Thalmann 2018 Healthcare Conference

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT), announced it intends to present at the Ladenburg Thalmann 2018 Healthcare Conference. The conference is being held on October 2, 2018, at the Sofitel Hotel in New York City.

Intuitive Venture PartnersOctober 1, 2018innovate biopharmaceuticals, 2018

Innovate Biopharmaceuticals Reports Second Quarter 2018 Earnings and Key Corporate Highlights

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) reported its second quarter 2018 financial results and key highlights.

Intuitive Venture PartnersAugust 15, 2018innovate biopharmaceuticals, 2018

Innovate Biopharmaceuticals, Inc. added to membership of Russell 3000®, 2000® and the Russell Microcap® Indexes

Innovate Biopharmaceuticals Inc. (NASDAQ: INNT) announced today that it has been added as a member of the broad-market Russell 3000®, 2000® and Microcap® Indexes as part of the 2018 Russell indexes reconstitution.

Intuitive Venture PartnersJune 25, 2018innovate biopharmaceuticals, 2018

Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of Anna Kazanchyan, M.D.

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) today announced the appointment of Saira Ramasastry, to its Board of Directors (Board).

Intuitive Venture PartnersJune 13, 2018innovate biopharmaceuticals, 2018

Innovate Biopharmaceuticals Scheduled to Present at BIO 2018 Convention in Boston on June 5, 2018

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory disease, intends to present on larazotide for celiac disease at BIO 2018 in Boston on Tuesday, June 5th.

Intuitive Venture PartnersMay 22, 2018innovate biopharmaceuticals, 2018